Patents Examined by Amber D. Steele
  • Functionally modified polypeptides and radiobiosynthesis
    Patent number: 11214820
    Abstract: Provided herein are compositions and methods for generating polypeptides using non-natural amino acids (nnAAs) and genetic machinery, wherein the modified polypeptides, such as therapeutic polypeptides, bind to albumin, such as serum albumin. Methods of substituting a non-natural amino acid in a first polypeptide to obtain a modified polypeptide, the nnAA in some instances comprising an albumin targeting group, are disclosed, as are methods for making populations of such modified polypeptides. A therapeutic polypeptide, interleukin-1 receptor antagonist (IL-1RA) is exemplified using the disclosed methods.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: January 4, 2022
    Assignee: Ikaria Inc.
    Inventor: Stephen DiMagno
  • Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
    Patent number: 11207423
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: December 28, 2021
    Assignee: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • GLP-1R/GCGR dual target agonist polypeptide for treatment of fatty liver diseases, hyperlipemia and arteriosclerosis
    Patent number: 11197914
    Abstract: The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Characterized by high enzymolysis stability, high biological activity and no adverse reaction, the polypeptide compounds are capable of reducing abnormal increase of triglycerides and total cholesterol in blood induced by diabetes mellitus and high fat diet, reducing liver enzyme level, reducing liver injury and fibrosis stage, and preventing or treating non-alcoholic fatty liver diseases (NAFLDs), hyperlipemia and arteriosclerosis.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: December 14, 2021
    Inventors: Xianxing Jiang, Rui Wang
  • Polypeptide having analgesic activity and use thereof
    Patent number: 11192921
    Abstract: A polypeptide with analgesic activity and use thereof is disclosed. The polypeptide has the amino acid sequence of Xa-Xb-Cys-Ser-Thr-Pro-Pro-Xc-Xd-Val-Leu-Tyr-Xe (SEQ ID NO: 1), or a pharmaceutically acceptable salt thereof, wherein the Xa is Gly or deleted, the Xb is one of Ser or Lys; the Xc is one of d-Cys or Ser or Asp, the Xd is Ala or deleted; and the Xe is Cys or Ser. One pair of disulfide bonds are formed between two cysteines in the sequence. The polypeptide has good inhibitory effects on physicochemical irritating pain and pathological and neuropathic pain, and has good analgesic effects in various experimental models. The specific effects of the polypeptide are to significantly increase the threshold of pain of mice, prolong the heat tolerance time of mice, and the adverse reactions such as spontaneous movement and excitability of mice are lower than normal values.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: December 7, 2021
    Assignee: NANJING ANJI BIOLOGICAL TECHNOLOGY CO., LTD
    Inventors: Hanmei Xu, Chen Liu
  • VSIG8-based chimeric proteins
    Patent number: 11192934
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • VSIG8-based chimeric proteins
    Patent number: 11192933
    Abstract: The present invention relates, in part, to chimeric proteins which include the extracellular domain of V-set and immunoglobulin domain-containing protein 8 (VSIG8) and their use in the treatment of diseases, such as immunotherapies for cancer and/or inflammatory diseases.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 7, 2021
    Assignee: Shattuck Labs, Inc.
    Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
  • Central nervous system homing peptides and uses thereof
    Patent number: 11174287
    Abstract: The present invention provides homing peptides that localize in central nervous system tissue characterized by neuroinflammation and methods of using the same.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 16, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Kamal Moudgil, Bodhraj Acharya
  • Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
    Patent number: 11141460
    Abstract: Provided herein are methods of using 7?-hydroxy-4-cholesten-3-one (C4) in predicting the clinical sensitivity to treatment of bile acid-related and associated disorders with treatment peptides, such as variants of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics) and fusions of FGF19 and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), and variants of fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics).
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: October 12, 2021
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Alexander Mark Depaoli, Jian Luo, Hui Tian
  • Polypeptides and medical uses thereof
    Patent number: 11136374
    Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 5, 2021
    Assignee: COLZYX AB
    Inventors: Matthias Mörgelin, Suado Abdillahi
  • Peptide hydrogel properties and its applications
    Patent number: 11135163
    Abstract: Peptide hydrogels having a self-assembling, 3-dimensional nanofiber matrix are described. The nanofiber matrix comprises an amphiphilic peptide and optionally albumin. The peptide comprises (consists of) a terminal hydrophobic region, a central turning region, and a terminal hydrophilic region. Methods of making such hydrogels are also described, along with methods of using the hydrogels as scaffolding for tissue engineering, hemostatic agents, as well as 3-dimensional cell cultures, and for drug delivery, encapsulation of active agents (therapeutic cells, molecules, drugs, compounds), cell transplantation, cell storage, virus culture and storage.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: October 5, 2021
    Assignee: Kansas State University Research Foundation
    Inventors: Xiuzhi S. Sun, Hongzhou Huang, Tiffany L. Carter, Mark L. Weiss
  • Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
    Patent number: 11136353
    Abstract: Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: October 5, 2021
    Assignee: Qwixel Therapeutics LLC
    Inventors: David Stover, Sherie Morrison, Alex Vasuthasawat, Kham Trinh, George Ayoub
  • Antimicrobial peptides and their use
    Patent number: 11130781
    Abstract: The invention relates to the field of antibiotics, more specifically to peptide antibiotics, such as antimicrobial peptides and their use in the treatment of diseases associated with microbial infections. In particular, the invention provides a peptide with antimicrobial activity comprising an amino acid sequence RRWVQRWIRRWR (SEQ ID NO: 24) or an analogue thereof.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: September 28, 2021
    Assignees: Universiteit Utrecht Holding B.V., UMC Utrecht Holding B.V.
    Inventors: Marinus Van Eijk, Albert Van Dijk, Hendrik Peter Haagsman, Cornelis Korstiaan Van Der Ent
  • Photoactivated crosslinking of a protein or peptide
    Patent number: 11097033
    Abstract: A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: August 24, 2021
    Assignee: Cook Medical Technologies LLC
    Inventors: Alan George Brownlee, Christopher Malcolm Elvin, Jerome Anthony Werkmeister, John Alan Maurice Ramshaw, Charles Mark Lindall
  • Methods and compositions for inhibiting cancer cell growth
    Patent number: 11078256
    Abstract: Described are methods and compositions that provide for generating synthetic or recombinant proline rich peptides. In some aspects, p1978 compositions are used to inhibit breast cancer cell growth and thus provided is a method for treating and preventing breast cancer cell growth in a mammal.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: August 3, 2021
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Charles F. Streckfus
  • Caspofungin compositions for inhalation
    Patent number: 11071768
    Abstract: Compositions and corresponding methods for the treatment and/or prevention of a fungal infection in the pulmonary system of a subject in need thereof with caspofungin or a derivative thereof are disclosed herein.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 27, 2021
    Assignee: TRILOGY THERAPEUTICS, INC.
    Inventors: David M. Ryckman, Iching G. Yu
  • Use of therapeutic agents
    Patent number: 11066671
    Abstract: The specification relates to the use of Mcl-1 inhibitors to promote apoptosis in vascular endothelial cells undergoing neovascularisation in disease states.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: July 20, 2021
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Leigh Coultas, Grant Dewson, Emma Watson
  • Self-assembly of protein-based biomaterials with multiple morphologies
    Patent number: 11059872
    Abstract: The present disclosure relates, in some embodiments, to a composition comprising a biomaterial. A biomaterial may comprise, for example, one or more molecules capable of self-association and/or self-assembly. In some embodiments, a biomaterial may comprise one or more polypeptides and/or proteins. A biomaterial may comprise, for example, two or more self-assembled Ultrabithorax (Ubx) protein molecules. A Ubx protein, in some embodiments, may be any wild type Drosophila melanogaster Ultrabithorax protein, including any natural or non-natural isoforms (e.g., alternative splicing isoforms). The present disclosure relates, in some embodiments, to a method of making a biomaterial comprising contacting two or more Ubx protein molecules under conditions that permit self-assembly to form a first fibril and contacting the first fibril to a second fibril.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: July 13, 2021
    Assignee: BONDWELL TECHNOLOGIES LP
    Inventors: Sarah E. Bondos, Alexandra M. Greer, Kathleen S. Matthews, Zhao Huang, Autumn Brawley, Jan Patterson
  • Antimicrobial peptides and methods of making and using same
    Patent number: 11059855
    Abstract: The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: July 13, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Charles H. Chen, Martin B. Ulmschneider
  • Methods and compositions for treating cystic fibrosis
    Patent number: 11052132
    Abstract: The present disclosure provides a method of treating diseases or disorders associated with CFTR protein dysfunction, including Cystic Fibrosis, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 6, 2021
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Susan Arnold, David James Ballance
  • Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
    Patent number: 11041000
    Abstract: The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 22, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan